Skip to main content

Glaxo Wellcome Licenses Rosetta s Resolver Software

NEW YORK, Dec 11 - Rosetta Inpharmatics said Monday that it had licensed its Resolver Expression Data Analysis System to Glaxo Wellcome.

Glaxo Wellcome will use the system, which is exclusively distributed by Agilent Technologies, to to analyze gene expression data.

The Resolver software can be used with a variety of DNA chip technologies, including Agilent’s microarrays and Affymetrix GeneChip microarrays.

" It significantly complements our in-house development programs and will help maintain the company's position at the leading edge of applying genomics technologies in the pursuit of new treatments,” said Eric Meldrum, group leader for molecular and cellular biology at Glaxo Wellcome.

Glaxo Wellcome was not immediately available to comment on its decision to license the Resolver software.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.